BioCentury
ARTICLE | Finance

ASH to ashes

Examining investor behavior around ASH

December 14, 2015 8:00 AM UTC

Fueled by the emergence of data on gene therapies and CAR T therapies for hematologic diseases a year ago, investors have now begun to watch ASH milestones as closely as they have always watched ASCO. But ASH seems to have brought out the bears.

For the American Society of Clinical Oncology conference, the name of the game was tracking down and rewarding early clinical data presentations. In contrast, the American Society of Hematology meeting saw investors bidding up names upon the release of abstracts ahead of the event and then selling after the updates were actually presented...